Oral composition, soft capsule, and method for producing oral composition
By using glycerol fatty acid esters as stabilizers in oral compositions, the stability problem of arachidonic acid in combination with lutein and zeaxanthin was solved, resulting in a composition that is not easily separated, thus ensuring the stability and uniformity of the composition.
Patent Information
- Application Number
- CN202480021895.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-04-05
- Filing Date
- 2024-04-01
- Publication Date
- 2025-11-18
AI Technical Summary
When arachidonic acid is combined with lutein, zeaxanthin and their fatty acid esters, the stability of the composition is difficult to maintain, component separation is likely to occur, affecting the appearance of the composition and the formulation of the active ingredients.
Using glycerol fatty acid esters as stabilizers, glycerol monoesters and/or diesters of saturated fatty acids with 12 to 24 carbon atoms are selected and combined with arachidonic acid compounds, lutein, zeaxanthin and their fatty acid esters, and the content ratio of component (C) is controlled to be 0.40 to 20, forming an oral composition that is not easily separated.
A stable combination of arachidonic acid compounds, lutein, zeaxanthin, and their fatty acid esters was achieved, avoiding component separation and ensuring the stability of the composition and the uniform distribution of the active ingredients.
Smart Images

Figure BDA0005613142030000171 
Figure BDA0005613142030000181 
Figure BDA0005613142030000201
Abstract
Description
TECHNICAL FIELD
[0001] The present application relates to an oral composition and a method for producing the same. Furthermore, the present application relates to a soft capsule containing the above-mentioned oral composition. BACKGROUND
[0002] Carotenoids are antioxidant substances produced in plants, algae, bacteria, and the like, and are rich in vegetables or fruits, and are known to have strong antioxidant effects (Non-Patent Literature 1, Non-Patent Literature 2). It is reported that there are 16 kinds of carotenoids in the human brain (Non-Patent Literature 3), and among them, lutein and zeaxanthin (Non-Patent Literature 4), which are known to be rich in komatsuna and the like, are known to have a neuroprotective effect based on antioxidant effects in the nervous system of the brain (Non-Patent Literature 5, Non-Patent Literature 6).
[0003] On the other hand, arachidonic acid (hereinafter also referred to as ARA) which is present in meat, seafood, eggs, and the like is known to have various physiological activities. As a composition containing ARA, for example, Patent Literature 1 discloses a composition containing ARA as a constituent fatty acid, which has an effect of improving the decline in higher brain function due to organic brain damage.
[0004] PATENT LITERATURE Patent Literature 1: Japanese Patent Application Publication No. 2016-172770
[0005] NON-PATENT LITERATURE Non-Patent Literature 1: Manochkumar, J. et al. Phyto medicine 91, 153676 (2021). Non-Patent Literature 2: Maoka, T. J. Nat. Med. 74, 1-16 (2020). Non-Patent Literature 3: Craft, N. E. et al. J. Nutr. Health Aging 8, 156-162 (2004). Non-Patent Literature 4: Aizawa, K. & Inakuma, T. Food Sci. Technol. Res. 13, 247-252 (2007). Non-Patent Literature 5: Singhrang, N. et al. J. Biomed. Pharmacother. 103, 582-587 (2018). Non-Patent Literature 6: Hu, Y. et al. J. Nutr. Sci. Vitaminol. (Tokyo). 67, 234-242 (2021). SUMMARY
[0006] Arachidonic acid and carotenoids are increasingly in demand as health foods because of their various physiological activities. However, it has been found that when arachidonic acid is combined with at least one compound selected from the group consisting of lutein, zeaxanthin and fatty acid esters thereof, it is difficult to maintain the stability of the composition, and separation of the components tends to occur. If the components of the composition separate, there are problems such as poor appearance of a product using the composition, or difficulty in properly formulating the desired amount of the active ingredient into the product using the composition.
[0007] An object of the present application is to provide an oral composition containing an arachidonic acid compound and at least one compound selected from the group consisting of lutein, zeaxanthin and fatty acid esters thereof, which is not easily separated.
[0008] The present inventors have conducted intensive studies in order to solve the above problem, and as a result, have found that a composition containing an arachidonic acid compound and at least one compound selected from the group consisting of lutein, zeaxanthin and fatty acid esters thereof, which uses a glycerol monoester and / or a glycerol diester in which the constituent fatty acid is a saturated fatty acid having a carbon number of 12 to 24, becomes an oral composition which is not easily separated.
[0009] The present application encompasses the following oral composition and the like. [1] An oral composition characterized by containing component (A): an arachidonic acid compound, component (B): at least one compound selected from the group consisting of lutein, zeaxanthin and fatty acid esters thereof, and component (C): a glycerol fatty acid ester (s), and the above glycerol fatty acid ester (s) is a glycerol monoester and / or a glycerol diester in which the constituent fatty acid is a saturated fatty acid having a carbon number of 12 to 24. [2] The oral composition according to the above [1], characterized in that the content of the above component (C) is 0.40 to 20 by weight relative to the total content of the above component (A) (arachidonic acid conversion) and the above component (B) (free form conversion) ((C) / ((A) + (B))). [3] The oral composition according to the above [1] or [2], characterized in that the above arachidonic acid compound is at least one compound selected from the group consisting of arachidonic acid, a salt thereof and a compound containing arachidonic acid as a constituent fatty acid. [4] The oral composition according to any one of the above [1] to [3], characterized in that the content of the above component (C) is 4 to 25% by weight. [5] The oral composition according to any one of the above [1] to [4], characterized by being used for filling a soft capsule. [6] A soft capsule characterized by having a content containing the oral composition according to any one of the above [1] to [5] and a coating film. [7] A method for producing an oral composition, characterized by comprising a step of mixing component (A): an arachidonic acid compound, component (B): a compound selected from at least one of lutein, zeaxanthin and a fatty acid ester thereof, and component (C): a glycerol fatty acid ester (s) which is a glycerol monoester and / or a glycerol diester in which the constituent fatty acid is a saturated fatty acid having 12 to 24 carbon atoms.
[0010] According to the present application, an oral composition which contains an arachidonic acid compound and at least one compound selected from lutein, zeaxanthin and a fatty acid ester thereof and which is not easily separated can be provided. DETAILED DESCRIPTION
[0011] The oral composition of the present application contains component (A): an arachidonic acid compound, component (B): a compound selected from at least one of lutein, zeaxanthin and a fatty acid ester thereof, and component (C): a glycerol fatty acid ester (s).
[0012] (Component (A): arachidonic acid compound) As the arachidonic acid compound, arachidonic acid (free arachidonic acid), a salt thereof and a derivative thereof can be used. As the salt of arachidonic acid, for example, a calcium salt, a sodium salt and the like can be exemplified. As the derivative of arachidonic acid, for example, a compound having a structure in which arachidonic acid is bonded and a compound from which arachidonic acid can be separated by hydrolysis can be used. As the compound from which arachidonic acid can be separated by hydrolysis, a compound containing arachidonic acid as a constituent fatty acid can be exemplified. The arachidonic acid compound can be used alone as one kind or two or more kinds can be used in combination.
[0013] The arachidonic acid compound used in the present application is preferably a compound selected from free arachidonic acid, a salt thereof and a compound containing arachidonic acid as a constituent fatty acid.
[0014] As the compound containing arachidonic acid as a constituent fatty acid, a compound selected from a triglyceride in which a part or all of the constituent fatty acids are arachidonic acid, a diglyceride in which a part or all of the constituent fatty acids are arachidonic acid, a monoglyceride in which the constituent fatty acid is arachidonic acid, a phospholipid in which a part or all of the constituent fatty acids are arachidonic acid, a glycolipid in which a part or all of the constituent fatty acids are arachidonic acid and an alcohol ester of arachidonic acid is preferable.
[0015] Among them, as the arachidonic acid compound, more preferably, a triglyceride, a diglyceride, and a phospholipid in which a part or all of the fatty acids are arachidonic acid, further preferably, a triglyceride and a diglyceride in which a part or all of the fatty acids are arachidonic acid, particularly preferably, a triglyceride in which a part or all of the fatty acids are arachidonic acid.
[0016] The arachidonic acid compound used in the present application is not limited in any way by its form or production method, and a chemically synthesized product, a substance from a natural product, or a substance from a genetically recombined organism (E. coli, yeast, plants, etc.) can be used. As the substance from a natural product, a substance from aquatic organisms, algae, microorganisms, plants (mosses, etc.) having arachidonic acid compound production ability can be exemplified.
[0017] Among them, the arachidonic acid compound is preferably derived from a microorganism. As the microorganism, for example, a microorganism belonging to the genus Mortierella, the genus Conidiobolus, the genus Pythium, the genus Phytophthora, the genus Penicillium, the genus Cladosporium, the genus Mucor, the genus Fusarium, the genus Aspergillus, the genus Rhodotorula, the genus Entomophthora, the genus Echinosporangium, and the genus Saprolegnia can be exemplified.
[0018] Further, an arachidonic acid compound extracted and / or refined from a natural product or the like containing the arachidonic acid compound can be used, or the raw material itself can be directly used so that the arachidonic acid compound is contained in the oral composition of the present application. As the raw material containing the arachidonic acid compound, for example, an edible oil such as an oil produced by a microorganism, an oil extracted from an egg, meat, a marine product, etc. can be exemplified. The production method of the arachidonic acid compound using a microorganism is not limited, and a publicly known method such as the method described in Patent Document 1 can be used. In one mode, the oral composition of the present application can contain an oil, and the arachidonic acid compound is a part of the oil.
[0019] (Component (B): Lutein, zeaxanthin, and fatty acid esters thereof) The oral composition of the present invention contains at least one compound selected from lutein, zeaxanthin, and their fatty acid esters. Lutein and zeaxanthin are types of carotenoids. As component (B), one or more of lutein (free lutein, also known as free lutein), zeaxanthin (free zeaxanthin, also known as free zeaxanthin), fatty acid esters of lutein, and fatty acid esters of zeaxanthin can be used. Lutein, zeaxanthin, and their fatty acid esters can be prepared, for example, by extraction from plants. Lutein, zeaxanthin, and their fatty acid esters are found in, for example, green and yellow vegetables such as spinach, kale, broccoli, pumpkin, carrots, and green peppers; fruits such as oranges, peaches, papayas, plums, mangoes, avocados, raspberries, and rose hips; and marigold petals, etc.
[0020] Lutein fatty acid esters are fatty acid esters in which one or two hydroxyl groups of lutein are bonded to fatty acids. Examples of fatty acids in lutein fatty acid esters include fatty acids with 4 to 20 carbon atoms, with fatty acids having 8 to 18 carbon atoms being preferred. The oral composition may contain one or more types of lutein fatty acid esters. Lutein is generated by hydrolyzing lutein fatty acid esters.
[0021] Zeaxanthin fatty acid esters are fatty acid esters in which one or two hydroxyl groups of zeaxanthin are bonded to fatty acids. Examples of fatty acids in zeaxanthin fatty acid esters include fatty acids with 4 to 20 carbon atoms, preferably fatty acids with 8 to 18 carbon atoms. The oral composition may contain one or more types of zeaxanthin fatty acid esters. Zeaxanthin is generated by hydrolyzing zeaxanthin fatty acid esters.
[0022] In this invention, as long as the effects of this invention can be achieved, the oral composition of this invention may also contain plant-derived raw materials rich in at least one of lutein, lutein fatty acid esters, zeaxanthin, and zeaxanthin fatty acid esters. Examples of plant-derived raw materials include, for instance, plant-extracted oils. Lutein, zeaxanthin, and their fatty acid esters are also available in commercially available products.
[0023] The oral composition of the present invention preferably contains free lutein. The oral composition of the present invention preferably contains free zeaxanthin. As component (B), the oral composition of the present invention preferably contains lutein and / or zeaxanthin.
[0024] The oral composition of the present invention may contain only lutein and / or its fatty acid esters as component (B), or may contain only zeaxanthin and / or its fatty acid esters, preferably containing lutein and zeaxanthin. The ratio of lutein to zeaxanthin in the oral composition of the present application is not particularly limited, and the weight ratio of lutein to zeaxanthin (lutein:zeaxanthin) is preferably 20:1 to 1:1, more preferably 10:1 to 2:1.
[0025] (Ingredient (C): glycerol fatty acid ester (s)) The oral composition of the present application contains a glycerol fatty acid ester (s). The above glycerol fatty acid ester (s) is a glycerol monoester and / or a glycerol diester in which the constituent fatty acid is a saturated fatty acid having a carbon number of 12 to 24. When the above glycerol fatty acid ester (s) is contained, the oral composition of the present application is less likely to separate.
[0026] In the present application, the glycerol fatty acid ester (s) is a glycerol monoester in which the constituent fatty acid is a saturated fatty acid having a carbon number of 12 to 24 and / or a glycerol diester in which the constituent fatty acid is a saturated fatty acid having a carbon number of 12 to 24. The glycerol monoester in which the constituent fatty acid is a saturated fatty acid having a carbon number of 12 to 24 is a compound in which one of the three hydroxyl groups of glycerol is ester-bonded to a saturated fatty acid having a carbon number of 12 to 24. The glycerol diester in which the constituent fatty acid is a saturated fatty acid having a carbon number of 12 to 24 is a compound (glycerol difatty acid ester) in which two of the three hydroxyl groups of glycerol are ester-bonded to a saturated fatty acid having a carbon number of 12 to 24. In the present specification, the "glycerol fatty acid ester" is a fatty acid glycerol monoester and / or a fatty acid glycerol diester.
[0027] As the saturated fatty acid having a carbon number of 12 to 24, lauric acid, myristic acid, pentadecanoic acid, palmitic acid, margaric acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, and the like can be exemplified. The saturated fatty acid having a carbon number of 12 to 24 is preferably a saturated fatty acid having a carbon number of 12 to 22. As a specific example of the glycerol monoester or glycerol diester containing a saturated fatty acid having a carbon number of 12 to 24 as the constituent fatty acid, lauric acid glycerol monoester, lauric acid glycerol diester, palmitic acid glycerol monoester, palmitic acid glycerol diester, stearic acid glycerol monoester, stearic acid glycerol diester, behenic acid glycerol monoester, behenic acid glycerol diester, and the like can be exemplified. In the glycerol fatty acid ester (s), the constituent fatty acid can be one selected from saturated fatty acids having a carbon number of 12 to 24, or two or more kinds thereof. The glycerol fatty acid ester (s) can also be referred to as a glycerol monoester and / or a glycerol diester in which the constituent fatty acid is one or two or more kinds selected from saturated fatty acids having a carbon number of 12 to 24.
[0028] The glycerol fatty acid ester (s) is a glycerol monoester and / or a glycerol diester in which the constituent fatty acid is a saturated fatty acid having a carbon number of 12 to 24, and the proportion of the saturated fatty acid having a carbon number of 12 to 22 in the constituent fatty acid is preferably 90% by weight or more, more preferably 95% by weight or more, and further preferably 98% by weight or more.
[0029] The above glycerol fatty acid ester (s) can be one or two or more. When the oral composition of the present application contains two or more glycerol fatty acid esters as the above glycerol fatty acid ester (s), the combination thereof is not particularly limited, and for example, when two or more glycerol fatty acid esters (s) having different carbon numbers constituting the fatty acid are contained, the oral composition of the present application is less likely to be separated. As the combination of two or more glycerol fatty acid esters (s), for example, the combination of glycerol monopalmitate and glycerol monostearate, the combination of glycerol monostearate, glycerol distearate, glycerol monobehenate and glycerol dibehenate, and the like are preferred.
[0030] The synthesis of the glycerol monoester and / or glycerol diester in which the constituent fatty acid is a saturated fatty acid having a carbon number of 12 to 24 can be performed by a publicly known method. The glycerol fatty acid ester (s) can generally be produced by an esterification reaction of a saturated fatty acid and glycerol. A commercially available emulsifier in which the glycerol fatty acid ester (s) is a main component can also be used in the component (C). When a commercially available emulsifier is used, the emulsifier preferably contains more than 50% by weight of the glycerol fatty acid ester (s). The content of the glycerol fatty acid ester (s) in the emulsifier is more preferably 60% by weight or more, further preferably 70% by weight or more, more preferably 80% by weight or more, particularly preferably 90% by weight or more. In one mode, the content of the glycerol fatty acid ester (s) in the emulsifier is preferably more than 50% by weight and 100% by weight or less, more preferably 60 to 100% by weight, further preferably 70 to 100% by weight, more preferably 80 to 100% by weight, particularly preferably 90 to 100% by weight, particularly preferably 95 to 100% by weight, particularly preferably 98 to 100% by weight, most preferably 99 to 100% by weight. In the present application, the emulsifier preferably does not contain an unsaturated fatty acid as the constituent fatty acid.
[0031] As long as the effects of the present application are not impaired, the composition of the present application can also contain a glycerol fatty acid ester other than the glycerol fatty acid ester (s) (referred to as another glycerol fatty acid ester). As the other glycerol fatty acid ester, for example, a glycerol fatty acid ester in which the constituent fatty acid does not contain an unsaturated fatty acid is preferred. The proportion of saturated fatty acids having a carbon number of 12 to 24 in the total constituent fatty acids of the glycerol fatty acid ester(s) contained in the composition of the present application is preferably 90 to 100% by weight, more preferably 95 to 100% by weight, further preferably 98 to 100% by weight, and particularly preferably 99 to 100% by weight. In one mode, when the composition of the present application contains glycerol fatty acid ester(s) and other glycerol fatty acid esters, the proportion of saturated fatty acids having a carbon number of 12 to 24 in the total constituent fatty acids of the glycerol fatty acid ester(s) contained in the composition of the present application is preferably 90% by weight or more and less than 100% by weight, more preferably 95% by weight or more and less than 100% by weight, further preferably 98% by weight or more and less than 100% by weight, and particularly preferably 99% by weight or more and less than 100% by weight.
[0032] As the above commercially available emulsifier using glycerol fatty acid ester(s) as the main component which can be used in the present application, for example, RIKEMAL S-100, RIKEMAL S-100P, RIKEMAL S-100A, RIKEMAL H-100, POEM V-100 (Japanese trade name), POEM PV-100 (Japanese trade name) (both of which are main components: glycerol monostearate), RIKEMAL B-100 (main component: glycerol monobehenate), POEM M-300 (Japanese trade name) (main component: glycerol monolaurate), and the like (all of which are manufactured by RIKEN VITAMIN CO., LTD.) can be exemplified.
[0033] The constituent fatty acids of the glycerol fatty acid ester and the number of unsaturated bonds of the constituent fatty acids can be determined, for example, by a gas chromatography (GC) method.
[0034] The content of the component (A): arachidonic acid compound (converted into arachidonic acid) contained in the oral composition of the present application is not particularly limited, and, for example, it is preferably 0.5% by weight or more, more preferably 1.0% by weight or more, further preferably 1.5% by weight or more, and, in addition, it is preferably 50% by weight or less, more preferably 45% by weight or less, further preferably 40% by weight or less, and particularly preferably 35% by weight or less, in the oral composition. In one mode, the content of the arachidonic acid compound (converted into arachidonic acid) is preferably 0.5 to 50% by weight, more preferably 1.0 to 45% by weight, further preferably 1.0 to 40% by weight, and particularly preferably 1.5 to 35% by weight, in the oral composition. When the content of the arachidonic acid compound is within the above range, the oral composition of the present application is less likely to be separated. The above content is the total content when two or more arachidonic acid compounds are contained. When the arachidonic acid compound is not free arachidonic acid, the arachidonic acid can be freed by saponification treatment or enzyme treatment, and the content can be converted into that of free arachidonic acid. The content of arachidonic acid can be determined by a GC method. The oral composition of the present application can contain the docosahexaenoic acid compound and the eicosapentaenoic acid compound described later, and the content of the arachidonic acid compound (converted into arachidonic acid) in the oral composition can also be 4 to 32% by weight.
[0035] The total content of the component (B) : lutein, zeaxanthin and their fatty acid esters contained in the oral composition of the present application is not particularly limited and can be set according to the form thereof and the like. The total content of the component (B) in the oral composition of the present application (converted into free form) is, for example, preferably 0.01% by weight or more, more preferably 0.1% by weight or more, and furthermore preferably 14% by weight or less, preferably 11% by weight or less. In one mode, the total content of the component (B) (converted into free form) in the oral composition is preferably 0.01 to 14% by weight, more preferably 0.1 to 11% by weight. When the total content of the component (B) is within the above range, the separation of the oral composition of the present application is more inhibited. Furthermore, the oral composition of the present application can effectively exert the physiological function of lutein, zeaxanthin and / or their fatty acid esters.
[0036] With respect to the component (B), the expression "converted into free form" means "converted into lutein" with respect to lutein and / or its fatty acid ester, and "converted into zeaxanthin" with respect to zeaxanthin and / or its fatty acid ester. The expression "amount converted into lutein" or the like means the amount when the component (B) is lutein, and means a value obtained by multiplying the number of moles of the fatty acid ester of lutein by the molecular weight of lutein when the component (B) is the fatty acid ester of lutein. The expression "amount converted into zeaxanthin" or the like means the amount when the component (B) is zeaxanthin, and means a value obtained by multiplying the number of moles of the fatty acid ester of zeaxanthin by the molecular weight of zeaxanthin when the component (B) is the fatty acid ester of zeaxanthin. The amounts of lutein, zeaxanthin and their fatty acid esters can be measured by an HPLC (high performance liquid chromatography) method.
[0037] The content of the component (C) : glycerol fatty acid ester (s) in the oral composition of the present application is preferably 4% by weight or more, more preferably 10% by weight or more, and further preferably 15% by weight or more, relative to the total amount of the oral composition. In addition, it is preferably 25% by weight or less, and more preferably 22% by weight or less. In one mode, the content of the component (C) in the oral composition of the present application is preferably 4 to 25% by weight, more preferably 10 to 22% by weight, and further preferably 15 to 22% by weight. When the content of the component (C) relative to the total amount of the oral composition is within the above range, the oral composition is less likely to separate, and is stable. In addition, when the content of the component (C) relative to the total amount of the oral composition is 25% by weight or less, the viscosity of the oral composition does not become excessively high, and the workability when the oral composition is filled into a soft capsule, for example, is good. The content of the component (C) can be measured by a GC method or an HPLC method.
[0038] In the oral composition of the present application, the content of the above component (C) relative to the total content of the above component (A) (in terms of arachidonic acid) and the above component (B) (in terms of free form) ( (C) / ((A) + (B)) ) is preferably 0.40 to 20 by weight ratio. By containing the components (A), (B) and (C) in the above weight ratio, the oral composition of the present application is less likely to separate. The above weight ratio is more preferably 0.45 or more, further preferably 0.50 or more, and in addition, more preferably 18 or less. In one mode, the above weight ratio is more preferably 0.45 to 18, and further preferably 0.50 to 18.
[0039] In the oral composition of the present application, the weight ratio of the above component (A) (in terms of arachidonic acid) relative to the above component (B) (in terms of free form) ( (A) / (B) ) is preferably 0.1 or more, more preferably 0.5 or more, further preferably 1.5 or more, particularly preferably 1.9 or more, and in addition, preferably 40 or less, and more preferably 35 or less. In one mode, the weight ratio of the above component (A) (in terms of arachidonic acid) relative to the above component (B) (in terms of free form) ( (A) / (B) ) is preferably 0.1 to 40, more preferably 0.5 to 40, further preferably 1.5 to 35, and particularly preferably 1.9 to 35.
[0040] The form of the oral composition of the present application is not particularly limited, and can be a solid form (powder form, granule form, tablet form, etc.), a liquid form, a paste form, etc. The oral composition of the present application is preferably in a liquid form at 25°C. The oral composition of the present application is preferably a composition in which the components do not separate.
[0041] Arachidonic acid compounds, and lutein, zeaxanthin, and fatty acid esters thereof are contained in natural products or foodstuffs, and are compounds with eating experience. Therefore, from the viewpoint of safety, it is generally considered that arachidonic acid compounds, and lutein, zeaxanthin, and fatty acid esters thereof are less problematic even if taken daily. According to the present application, an oral composition that is high in safety and easy to take can be provided.
[0042] Arachidonic acid compounds are known to exert various health functions such as cognitive function improvement effects, immune function regulation effects, and the like. The oral composition of the present application, because it contains arachidonic acid compounds, can be used to obtain the above-mentioned effects exerted by arachidonic acid compounds.
[0043] Lutein, zeaxanthin, and fatty acid esters thereof are known to have, for example, nerve cell protective effects based on antioxidant effects in the brain nervous system, and the like. Therefore, the oral composition of the present application can be used to obtain the above-mentioned effects exerted by at least one selected from the group consisting of lutein, zeaxanthin, and fatty acid esters thereof.
[0044] The oral composition of the present application can be applied to either therapeutic use (medical use) or non-therapeutic use (non-medical use). By non-therapeutic, it is meant the concept of not including medical actions, i.e., surgery, treatment, or diagnosis of humans. The oral composition of the present application can be formed into the form of a foodstuff, a pharmaceutical, a quasi-drug, a feed, or the like. In the case of the oral composition of the present application, it can be a material or preparation or the like that is used by being formulated in a foodstuff, a pharmaceutical, a quasi-drug, a feed, or the like. By oral composition, it is meant a composition that is taken orally.
[0045] As a specific example of the oral composition of the present application, for example, a foodstuff, a pharmaceutical for oral use, a quasi-drug, a feed, or the like can be cited, and a foodstuff or a pharmaceutical for oral use is preferred, and a foodstuff is more preferred.
[0046] The oral composition of the present application can contain, in addition to the above-mentioned components (A) to (C), any additive, any component, as long as the effects of the present application are not impaired. These additives and components can be selected according to the form of the oral composition or the like, and general additives and components that can be used in oral compositions of foodstuffs, pharmaceuticals, quasi-drugs, feeds, or the like can be used. When the oral composition of the present application is formed into a foodstuff, a pharmaceutical, a quasi-drug, a feed, or the like, the manufacturing method is not particularly limited, and it can be manufactured by a general method.
[0047] As an arbitrary component, for example, an oily component can be cited. As an oily component, for example, highly unsaturated fatty acids other than the above-mentioned components (A) to (C), fats and oils, or the like can be cited. As the above-mentioned oily component, for example, docosahexaenoic acid compounds, eicosapentaenoic acid compounds, edible fats and oils and the like can be exemplified. The oral composition of the present application preferably further contains a docosahexaenoic acid compound and an eicosapentaenoic acid compound. The oral composition of the present application is an oral composition in which the components are not easily separated even when containing an oily component such as a docosahexaenoic acid compound and an eicosapentaenoic acid compound.
[0048] As the docosahexaenoic acid compound, docosahexaenoic acid (free DHA), a salt thereof and a derivative thereof can be used. As the derivative of docosahexaenoic acid, for example, a compound having a structure to which docosahexaenoic acid is bonded and a compound from which docosahexaenoic acid can be separated by hydrolysis can be used. As the compound from which docosahexaenoic acid can be separated by hydrolysis, a compound containing docosahexaenoic acid as a constituent fatty acid can be exemplified. The docosahexaenoic acid compound contained in the oral composition of the present application can be one kind or two or more kinds.
[0049] The docosahexaenoic acid compound used in the present application is preferably at least one kind selected from the group consisting of free docosahexaenoic acid, a salt thereof and a compound containing docosahexaenoic acid as a constituent fatty acid. As the salt of docosahexaenoic acid, for example, a calcium salt, a sodium salt and the like can be exemplified.
[0050] As the compound containing docosahexaenoic acid as a constituent fatty acid, a compound selected from the group consisting of a triglyceride in which a part or all of constituent fatty acids are docosahexaenoic acid, a diglyceride in which a part or all of constituent fatty acids are docosahexaenoic acid, a monoglyceride in which the constituent fatty acid is docosahexaenoic acid, a phospholipid in which a part or all of constituent fatty acids are docosahexaenoic acid, a glycolipid in which a part or all of constituent fatty acids are docosahexaenoic acid and an alcohol ester of docosahexaenoic acid is preferred. Among them, as the docosahexaenoic acid compound, a triglyceride, a diglyceride and a phospholipid in which a part or all of constituent fatty acids are docosahexaenoic acid are more preferred, a triglyceride and a diglyceride in which a part or all of constituent fatty acids are docosahexaenoic acid are further preferred, and a triglyceride in which a part or all of constituent fatty acids are docosahexaenoic acid is particularly preferred.
[0051] The docosahexaenoic acid compound used in the present application is not limited in any way by its form or manufacturing method, and can be a chemically synthesized product, a substance from a natural product, or a substance from a genetically recombined organism (E. coli, yeast, plants, etc.). As a substance from a natural product, there can be mentioned a substance from a water product or an alga, a fungus (Colwellia bacteria, Myxomycetes, etc.), a plant (moss, etc.) having DHA production ability. Among these, the docosahexaenoic acid compound is preferably from a water product. Further, the docosahexaenoic acid compound can be used as extracted and / or refined from a raw material such as a natural product containing the docosahexaenoic acid compound, or the raw material itself can be directly used to contain the docosahexaenoic acid compound in the composition. As the raw material containing the docosahexaenoic acid compound, there can be mentioned, for example, an edible oil and fat such as an oil extracted from fish oil, meat, milk, etc. As the fish oil containing the docosahexaenoic acid compound, a fish oil concentrated so as to have a content of the docosahexaenoic acid compound (docosahexaenoic acid equivalent) of 5% by weight or more, preferably 10% by weight or more, and more preferably 50% by weight or more is preferred. For example, the docosahexaenoic acid compound extracted and / or refined from the fish oil containing the docosahexaenoic acid compound can be used, or the fish oil itself can be directly used. In one mode, the oral composition of the present application contains fish oil, and the docosahexaenoic acid compound can be a part of the fish oil.
[0052] As the eicosapentaenoic acid compound, eicosapentaenoic acid (free eicosapentaenoic acid. Hereinafter also referred to as EPA), a salt thereof, and a derivative thereof can be used. The eicosapentaenoic acid compound can be used alone or in combination of two or more. As the derivative of eicosapentaenoic acid, for example, there can be mentioned a compound having a structure to which eicosapentaenoic acid is bonded and a compound from which eicosapentaenoic acid can be separated by hydrolysis. As the compound from which eicosapentaenoic acid can be separated by hydrolysis, there can be mentioned a compound containing eicosapentaenoic acid as a constituent fatty acid. The eicosapentaenoic acid compound is preferably at least one selected from the group consisting of free eicosapentaenoic acid, a salt thereof, and a compound containing eicosapentaenoic acid as a constituent fatty acid. As the salt of eicosapentaenoic acid, for example, there can be mentioned a calcium salt, a sodium salt, etc. As the compound containing eicosapentaenoic acid as a constituent fatty acid, it is preferably a compound selected from the group consisting of a triglyceride in which a part or all of constituent fatty acids are eicosapentaenoic acid, a diglyceride in which a part or all of constituent fatty acids are eicosapentaenoic acid, a monoglyceride in which the constituent fatty acid is eicosapentaenoic acid, a phospholipid in which a part or all of constituent fatty acids are eicosapentaenoic acid, a glycolipid in which a part or all of constituent fatty acids are eicosapentaenoic acid, and an alcohol ester of eicosapentaenoic acid. Among them, as the eicosapentaenoic acid compound, more preferable are triglyceride, diglyceride and phospholipid in which a part or all of the fatty acid is eicosapentaenoic acid, further preferable are triglyceride and diglyceride in which a part or all of the fatty acid is eicosapentaenoic acid, and particularly preferable is triglyceride in which a part or all of the fatty acid is eicosapentaenoic acid.
[0053] The eicosapentaenoic acid compound is not limited in terms of its form or production method, and can be a chemically synthesized product, a substance derived from a natural product, or a substance derived from a genetically recombined organism (E. coli, yeast, plant, etc.). As the substance derived from a natural product, there can be mentioned a substance derived from a water product or algae, fungi (myxomycetes, etc.), or plants (moss, etc.) having EPA production ability. Among them, the eicosapentaenoic acid compound is preferably derived from a water product. Further, the eicosapentaenoic acid compound can be used as it is extracted and / or refined from a natural product or the like containing the eicosapentaenoic acid compound, or the natural product or the like can be directly used to contain the eicosapentaenoic acid compound in the composition. As the natural product containing the eicosapentaenoic acid compound, there can be mentioned, for example, an edible oil such as oil extracted from fish oil, egg, meat, milk, or algae. As the fish oil containing the eicosapentaenoic acid compound, it is preferable to use fish oil in which the content of the eicosapentaenoic acid compound (converted into eicosapentaenoic acid) is 5% by weight or more, preferably 10% by weight or more, and more preferably 20% by weight or more. For example, the eicosapentaenoic acid compound can be used as it is extracted and / or refined from the fish oil containing the eicosapentaenoic acid compound, or the fish oil can be directly used.
[0054] The amount converted into DHA or the like, when the oral composition of the present application contains free DHA, means the amount of free DHA. When a eicosapentaenoic acid compound other than free DHA is contained, it means that DHA is freed from a compound containing DHA as a constituent fatty acid by saponification treatment or enzyme treatment, and the amount converted into free DHA. The amount converted into EPA or the like, when the oral composition of the present application contains free EPA, means the amount of free EPA. When a eicosapentaenoic acid compound other than free EPA is contained, it means that EPA is freed from a compound containing EPA as a constituent fatty acid by saponification treatment or enzyme treatment, and the amount converted into free EPA.
[0055] As the above oil component, the above edible oil, as long as it is an oil which can be orally taken by a human being, is not particularly limited, and for example, an edible oil which is liquid at normal temperature (25°C) or the like can be exemplified. As such an edible oil, for example, vegetable oils such as olive oil, sesame oil, rice germ oil, safflower oil, soybean oil, corn oil, rapeseed oil, palm oil, palm olein, palm kernel oil, sunflower seed oil, grape oil, cottonseed oil, coconut oil, peanut oil, and the like; medium-chain fatty acid triglyceride; squalene; fish oil; and the like can be exemplified. The fish oil can be a fish oil containing docosahexaenoic acid compounds and / or eicosapentaenoic acid compounds, or a fish oil not containing docosahexaenoic acid compounds and eicosapentaenoic acid compounds.
[0056] In the oral composition of the present application, one oil component can be used alone, or two or more oil components can be used in combination. As the oil component, docosahexaenoic acid compounds, eicosapentaenoic acid compounds are preferred. The oral composition of the present application preferably contains: a fish oil containing docosahexaenoic acid compounds, a fish oil containing eicosapentaenoic acid compounds, and / or a fish oil containing docosahexaenoic acid compounds and eicosapentaenoic acid compounds.
[0057] In the oral composition of the present application, the content of the above oil component is not particularly limited, and is preferably 10% by weight or more, relative to the total amount of the oral composition. When the content of the oil component is within the above range, the oral composition of the present application is less likely to be separated. The content of the oil component in the oral composition can be appropriately set depending on the use and the form, and for example, can be 20% by weight or more, or 40% by weight or more. In addition, for example, can be 90% by weight or less, or 80% by weight or less, or 70% by weight or less. In one mode, the content of the oil component in the oral composition of the present application can be 10 to 90% by weight, or 20 to 80% by weight, or 40 to 70% by weight. The composition and the content of the oil can be measured by gas chromatography (GC) method.
[0058] In the oral composition of the present application, the total content of the docosahexaenoic acid compounds in the oral composition of the present application is, for example, preferably 1% by weight or more, more preferably 10% by weight or more, and further preferably 80% by weight or less. In one mode, the total content of the docosahexaenoic acid compounds is preferably 1 to 80% by weight, more preferably 10 to 80% by weight, in the oral composition.
[0059] When the oral composition of the present application contains eicosapentaenoic acid compounds, the total content of the eicosapentaenoic acid compounds in the oral composition of the present application is preferably 1% by weight or more, more preferably 3% by weight or more, and in addition, preferably 40% by weight or less, more preferably 30% by weight or less. In one mode, the total content of the eicosapentaenoic acid compounds is preferably 1 to 40% by weight, more preferably 3 to 30% by weight, in the oral composition.
[0060] For example, when the oral composition of the present application is prepared as a drink food, the above ingredients (A) to (C) can be formulated with ingredients usable in a drink food (e.g., a food material, a food additive used as necessary, etc.) to prepare various drink foods. The drink food is not particularly limited, and for example, general drink foods, health foods, health aid foods, health beverages, functionally labeled foods, specified health foods, patient foods, etc. can be exemplified. The above health foods, health aid foods, functionally labeled foods, specified health foods, etc. can be used in various preparation forms such as granules, tablets, granules, powders, capsules, soft capsules, chewable tablets, dry syrups, syrups, liquids, beverages, drinks, liquid diets, etc.
[0061] When the oral composition of the present application is prepared as a pharmaceutical product or a quasi-pharmaceutical product, for example, the above ingredients (A) to (C) can be formulated with a pharmacologically acceptable carrier, an additive added as necessary, etc. to prepare a pharmaceutical product or a quasi-pharmaceutical product in various dosage forms. Such a carrier, an additive, etc. can be a pharmacologically acceptable carrier, an additive usable in a pharmaceutical product or a quasi-pharmaceutical product, and for example, one or two or more kinds of excipients, binders, disintegrants, lubricants, antioxidants, coloring agents, etc. can be exemplified. As the dosage form of the pharmaceutical product or the quasi-pharmaceutical product for oral administration, liquids, tablets, powders, granules, granules, sugar-coated tablets, capsules, soft capsules, suspensions, emulsions, chewable tablets, etc. can be exemplified.
[0062] When the oral composition of the present application is prepared as a feed, a mixture of the above ingredients (A) to (C) can be formulated in a feed. The feed also includes a feed additive. As the feed, for example, livestock feeds for cattle, pigs, chickens, sheep, horses, etc.; small animal feeds for rabbits, rats, mice, etc.; pet foods for dogs, cats, small birds, etc. can be exemplified.
[0063] The subject (which can also be referred to as an administration subject) who ingests or is administered the oral composition of the present application is not particularly limited. A human or a non-human mammal is preferred, and a human is more preferred.
[0064] The content of the arachidonic acid compound in the oral composition of the present application is preferably 10 to 500 mg, more preferably 20 to 400 mg, and further preferably 30 to 300 mg, in terms of arachidonic acid, per 1 day for an adult. The content of the lutein and / or the fatty acid ester thereof in the oral composition of the present application is preferably 0.5 to 200 mg, more preferably 1 to 100 mg, and further preferably 3 to 80 mg, in terms of lutein, per 1 day for an adult. The content of the zeaxanthin and / or the fatty acid ester thereof in the oral composition of the present application is preferably 0.1 to 50 mg, more preferably 0.1 to 30 mg, and further preferably 0.5 to 20 mg, in terms of zeaxanthin, per 1 day for an adult.
[0065] <Method for producing the oral composition> The oral composition of the present application can be produced, for example, by a method comprising a step of mixing the components (A), (B), and (C). The method for producing the oral composition of the present application comprises a step of mixing the component (A): an arachidonic acid compound, the component (B): a compound selected from at least one of lutein, zeaxanthin, and fatty acid esters thereof, and the component (C): a glycerol fatty acid ester(s) which is a glycerol monoester and / or a glycerol diester in which the constituent fatty acid is a saturated fatty acid having 12 to 24 carbon atoms. The order of mixing or the apparatus for mixing the arachidonic acid compound, the compound selected from at least one of lutein, zeaxanthin, and fatty acid esters thereof, and the glycerol fatty acid ester(s) is not particularly limited. The glycerol fatty acid ester(s) of the component (C) can be preferably dissolved by heating to 70 to 80°C, and then the mixture of the components (A) and (B) can be added to the glycerol fatty acid ester(s) to produce the oral composition of the present application by mixing and stirring. The apparatus for heating can be, for example, a water bath or the like. The apparatus for mixing and stirring can be, for example, a high-speed stirrer such as a bio-mixer, a homogenizer, a colloid mill, or a high-speed pulverizer. The content and the weight ratio of each component in the oral composition are as described above. Each component is preferably adjusted so as to be within the above-mentioned range.
[0066] The oral composition of the present application is preferably used as the content of a soft capsule. The oral composition of the present application is preferably used, for example, as a composition for filling a soft capsule.
[0067] <Soft capsule> The present application also provides a soft capsule having a content containing the above-mentioned oral composition and a coating film. The soft capsule of the present application is filled with the content of the above oral composition into a soft capsule formed with a film. The content can contain the above oral composition alone, or can contain other ingredients. As a base material for forming the film, a base material generally used in the film of a soft capsule (e.g., gelatin, starch, and the like) can be used.
[0068] <Method for producing soft capsule> The above oral composition can be formed into a soft capsule using a publicly known soft capsule molding machine, for example, in a heated state. The production of the soft capsule is not particularly limited, and can be produced according to the production conditions of the soft capsule sealing device.
[0069] In the present specification, a numerical range represented by a lower limit value and an upper limit value, i.e., "lower limit value - upper limit value", includes the lower limit value and the upper limit value. For example, a range represented by "1-2" means 1 or more and 2 or less, and includes 1 and 2. In the present specification, the upper limit and the lower limit can be set to a range based on any combination. Example
[0070] The present application will be described in more detail by way of examples below, but the scope of the present application is not limited by the examples.
[0071] Example 1 <Production of oral composition> First, 23.5 g of an arachidonic acid-containing edible oil and fat of microbial origin (ARA-containing edible oil and fat) and 1.2 g of a marigold pigment raw material (containing 20% by weight or more of lutein and 4% by weight or more of zeaxanthin) were added to a beaker, and mixed to prepare a mixed solution. Then, to uniformly disperse the marigold pigment raw material in the mixed solution, the mixed solution was stirred using a stirrer at a rotation speed of 200 rpm for 1 to 1.5 hours.
[0072] Next, 5.3 g of the glycerol fatty acid ester (C1) shown in Table 2 was dispensed into a polypropylene tube, and the glycerol fatty acid ester (C1) was dissolved by heating in a water bath set to 75°C. Then, the above prepared mixed solution was added to the polypropylene tube in which glycerol fatty acid ester (Cl) was dissolved. At this time, the temperature decreased due to the addition of the mixed solution, and glycerol fatty acid ester (Cl) was solidified. Therefore, in order to re-dissolve glycerol fatty acid ester (Cl), the mixture of the mixed solution and glycerol fatty acid ester (Cl) was heated in a water bath set at 75°C. After confirming that glycerol fatty acid ester (Cl) was re-dissolved, the mixture was stirred using a vortex mixer. Further, in order to uniformly dissolve the mixture, the mixture was heated again in a water bath set at 75°C. After confirming that the mixture was uniformly mixed, the polypropylene tube containing the mixture was taken out of the water bath, and the mixture was allowed to stand and cool at room temperature. This was used as an oral composition. In Table 1, the blending amount (g) of each raw material used in the preparation of the oral composition, the proportion of each component in the oral composition (wt%), and the weight ratio of each component are shown. In Table 2, the composition of glycerol fatty acid ester (Cl), the number of unsaturated bonds are shown. In Table 1 and Table 3 described later, the weight proportion (wt%) of arachidonic acid (A) is the arachidonic acid equivalent value of the weight of arachidonic acid contained in the oral composition, and the weight proportion of lutein and zeaxanthin (B) is the total of the lutein equivalent value of lutein and its fatty acid ester, and the zeaxanthin equivalent value of zeaxanthin and its fatty acid ester.
[0073] <Separation Evaluation> After the oral composition was allowed to stand and cool, the oral composition was scooped out from the polypropylene tube into a commercially available plastic cup using a spoon. At this time, the presence or absence of separation was evaluated by visual observation. The evaluation criteria are shown below. The results are shown in Table 2. ◎: No separation. O: Almost no separation (if a small amount of the oral composition is taken, liquid will seep from the surroundings). Δ: A part of the oral composition is separated. X: The oral composition is completely separated.
[0074] Examples 2 to 6 Examples 2 to 6 were prepared in the same manner as in Example 1, except that glycerol fatty acid ester (Cl) was changed to glycerol fatty acid esters (C2) to (C6) described in Table 2, and the separation evaluation was performed in the same manner as in Example 1. The results are shown in Table 2.
[0075] Comparative Examples 1 to 10 Comparative Examples 1 to 10 were prepared in the same manner as in Example 1, except that glycerol fatty acid ester (Cl) was changed to (poly)glycerol fatty acid esters (C'1) to (C'10) described in Table 2, and the separation evaluation was performed in the same manner as in Example 1. The results are shown in Table 2.
[0076] [Table 1]
[0077] [Table 2]
[0078] The "number of unsaturated bonds" in Table 2 shows the number of unsaturated bonds possessed by the constituent fatty acids of the glycerol fatty acid ester. The glycerol fatty acid esters (C1) to (C2) are mixtures of glycerol monoesters in which the constituent fatty acids are saturated fatty acids having a carbon number of 12 to 24 and glycerol diesters in which the constituent fatty acids are saturated fatty acids having a carbon number of 12 to 24. The glycerol fatty acid esters (C3) to (C6) contain glycerol monoesters in which the constituent fatty acids are saturated fatty acids having a carbon number of 12 to 24. The main constituent fatty acids of the glycerol fatty acid ester (C1) are palmitic acid (carbon number: 16, 4.2% by weight), stearic acid (carbon number: 18, 41.9% by weight), arachidic acid (carbon number: 20, 8.8% by weight), and behenic acid (carbon number: 22, 43.5% by weight). Of the constituent fatty acids of the glycerol fatty acid ester (C1), saturated fatty acids having a carbon number of 12 to 24 other than palmitic acid, stearic acid, arachidic acid, and behenic acid are 1.5% by weight. The main constituent fatty acids of the glycerol fatty acid ester (C4) are palmitic acid (carbon number: 16, 43.0% by weight) and stearic acid (55.1% by weight). Of the constituent fatty acids of the glycerol fatty acid ester (C4), saturated fatty acids having a carbon number of 12 to 24 other than palmitic acid and stearic acid are about 1.9% by weight. Of the constituent fatty acids of the glycerol fatty acid ester (C6), myristic acid (carbon number: 14) is 2.4% by weight, heptadecanoic acid (carbon number: 17) is 1.1% by weight, arachidic acid (carbon number: 20) is 1.4% by weight, stearic acid is 28.4% by weight, and palmitic acid is 65.3% by weight. Of the constituent fatty acids of the glycerol fatty acid ester (C6), saturated fatty acids having a carbon number of 12 to 24 other than myristic acid, heptadecanoic acid, arachidic acid, palmitic acid, and stearic acid are about 0.9% by weight. Analysis of the constituent fatty acids was outsourced to the General Incorporated Foundation, Japan Food Research Laboratories, and was performed by gas chromatography (hydrogen flame ionization detector, FID). For the glycerol fatty acid esters (C1) to (C6), saturated fatty acids having a carbon number of 12 to 22 are 90% by weight or more of the constituent fatty acids.
[0079] As shown in Table 2, the oral compositions of Examples 1 to 6 were not separated or almost not separated. The oral compositions of Comparative Examples 1 to 10 were completely separated or partially separated. The main component of the glycerol fatty acid ester used in Examples 1 to 6 is a glycerol monoester in which the constituent fatty acid is a saturated fatty acid having a carbon number of 12 to 24 and / or a glycerol diester in which the constituent fatty acid is a saturated fatty acid. A polyglycerol fatty acid ester was used in Comparative Examples 1, 2, 4, and 7 to 9. A glycerol fatty acid ester in which the constituent fatty acid has a carbon number of 8 was used in Comparative Example 6. The constituent fatty acid of the (poly)glycerol fatty acid ester (C') of Comparative Examples 3 to 5, 7 to 8, and 10 is an unsaturated fatty acid. Therefore, in the composition in which arachidonic acid and lutein and / or zeaxanthin are formulated, by containing the glycerol monoester and / or glycerol diester in which the constituent fatty acid is a saturated fatty acid having 12 to 24 carbons, separation of the composition is inhibited.
[0080] Examples 7 to 15 and Reference Example 1 <Study of the ratio of the components in the oral composition> The ratio of arachidonic acid, lutein and / or zeaxanthin and glycerol fatty acid ester was changed to prepare the oral composition. The oral composition in Examples 7 to 15 and Reference Example 1 was prepared in the same manner as in Example 1 except that the composition shown in Table 3 was changed. As to the obtained oral composition, separation evaluation was performed in the same manner as in Example 1. In Examples 7 to 15 and Reference Example 1, safflower oil was added to make the total weight of the oral composition 30 g. The glycerol fatty acid ester used was the glycerol fatty acid ester (C6) of Example 6. The results are shown in Table 3.
[0081] [Table 3]
[0082] As shown in Table 3, the oral compositions of Examples 7 to 15 had no separation or almost no separation. The value of glycerol fatty acid ester / (arachidonic acid + lutein + zeaxanthin) of the oral compositions of Examples 7 to 15 was 0.40 to 20, and the content of emulsifier was 4 to 25% by weight. Therefore, when the value of glycerol fatty acid ester / (arachidonic acid + lutein + zeaxanthin) in the oral composition is in the range of 0.40 to 20 and the content of emulsifier is in the range of 4 to 25% by weight, it is suggested that separation of the oral composition is inhibited. The oral composition of Reference Example 1 did not contain arachidonic acid compounds, but had no separation like Examples 7 to 15.
[0083] Examples 16 to 21 and Comparative Examples 11 to 20 <Preparation of the oral composition> The oral composition in Examples 16 to 21 and Comparative Examples 11 to 20 was prepared in the same manner as in Example 1 except that refined fish oil containing DHA and EPA was additionally added to the mixture of ARA-containing edible oil and the marigold pigment raw material, and separation evaluation was performed. The formulation amount (g) of the oral composition, the ratio of the components in the oral composition (% by weight), and the weight ratio of the components are shown in Table 4, and the composition, the number of unsaturated bonds, and the separation evaluation of the oral composition of glycerol fatty acid ester (C) and (poly)glycerol fatty acid ester (C') are shown in Table 5.
[0084] [Table 4]
[0085] [Table 5]
[0086] As shown in Table 5, the oral compositions of Examples 16 to 21 were not separated. The oral compositions of Comparative Examples 11 to 20 were completely separated or partially separated, like the oral compositions of Comparative Examples 1 to 10. The glycerol fatty acid esters (Cl) to (C6) used in Examples 16 to 21 are glycerol monoesters and / or glycerol diesters in which the constituent fatty acid is a saturated fatty acid. Therefore, even if the oral composition is formulated with arachidonic acid, DHA, EPA, and lutein and / or zeaxanthin, by containing glycerol monoesters and / or glycerol diesters in which the constituent fatty acid is a saturated fatty acid having a carbon number of 12 to 24, separation of the oral composition can be inhibited. In addition, it was confirmed that the oral compositions of the comparative examples had a tendency to have low viscosity, and the oral compositions of the examples had appropriate viscosity.
[0087] One example of a manufacturing example of a soft capsule is shown below.
[0088] Preparation of Soft Capsule Preparation Example 1 A gelatin solution having a viscosity of 2000 cp was prepared by dissolving gelatin in water at 50 to 60°C, at 100 parts by weight of gelatin and 35 parts by weight of food additive glycerol. Next, the raw materials were mixed by stirring in a ratio of 30 parts by weight of ARA-containing edible oil from a microbial source (containing 40% arachidonic acid), 48 parts by weight of safflower oil, 4 parts by weight of a raw material containing 20% lutein from marigold, and 18 parts by weight of glycerol fatty acid ester (containing 60% glycerol monostearate as a main component). Using the gelatin solution and the oral composition, capsule molding and drying were performed by a conventional method to manufacture soft capsules each containing 200 mg of the oral composition as a content.
[0089] In Preparation Example 1, soft capsules can also be manufactured using, for example, the oral compositions prepared in Examples 1 to 21 as the oral composition.
Claims
1. An oral composition, characterized in that, Ingredient (A): Arachidonic acid compounds. Component (B): A compound selected from at least one of lutein, zeaxanthin, and their fatty acid esters, and, Ingredient (C): Glyceryl fatty acid ester (S), Furthermore, the glycerol fatty acid ester(s) is a monoglyceride and / or diglyceride of a saturated fatty acid having 12 to 24 carbon atoms.
2. The oral composition according to claim 1, characterized in that, The weight ratio of the content of component (C) to the total content of component (A) (converted to arachidonic acid) and component (B) (converted to free matter), i.e., (C) / ((A)+(B)), is 0.40 to 20.
3. The oral composition according to claim 1, characterized in that, The arachidonic acid compounds are compounds selected from at least one of arachidonic acid, its salts, and compounds containing arachidonic acid as a constituent fatty acid.
4. The oral composition according to claim 1, characterized in that, The content of component (C) is 4-25% by weight.
5. The oral composition according to claim 1, characterized in that, Used for filling soft capsules.
6. A soft capsule, characterized in that, It has contents and a film containing the oral composition according to any one of claims 1 to 5.
7. A method for manufacturing an oral composition, characterized in that, The process comprising a mixture of ingredients (A): arachidonic acid compounds, ingredient (B): at least one compound selected from lutein, zeaxanthin and their fatty acid esters, and ingredient (C): glycerol fatty acid ester(s). The glycerol fatty acid ester(s) is a monoglyceride and / or diglyceride of a saturated fatty acid having 12 to 24 carbon atoms.
Citation Information
Patent Citations
Composition having ameliorating action on reduction in higher brain function caused by brain structural disorder
JP2016172770A
